TG Therapeutics, Inc., a clinical-stage biopharmaceutical company headquartered in New York, United States, operates within the Health Care sector, specifically under the Biotechnology industry. The company is publicly traded on the Nasdaq stock exchange, with its financial activities denominated in USD. As of November 5, 2026, TG Therapeutics closed at a price of $59.825 per share. The company’s stock has experienced significant volatility over the past year, reaching a 52-week high of $63.60 on November 1, 2026, and a 52-week low of $26.76 on March 11, 2026.
With a market capitalization of approximately $9.16 billion, TG Therapeutics is actively engaged in the acquisition, development, and commercialization of innovative pharmaceutical products. The company’s primary focus is on the treatment of cancer and other therapeutic needs, with a particular emphasis on hematological malignancies. Currently, TG Therapeutics is advancing two therapies aimed at addressing relapsed and refractory non-Hodgkin’s lymphoma, a type of cancer that affects the lymphatic system.
The company’s financial metrics reflect its growth potential and market position. Notably, TG Therapeutics has a price-to-earnings (P/E) ratio of 21.56, indicating investor confidence in its future earnings growth. This ratio is a critical measure for investors assessing the company’s valuation relative to its earnings.
TG Therapeutics continues to be a significant player in the biopharmaceutical industry, driven by its commitment to developing groundbreaking treatments for complex diseases. For more detailed information about the company’s activities, offerings, and financial performance, stakeholders are encouraged to visit their official website at www.tgtherapeutics.com or monitor their trading activity on the Nasdaq stock exchange.
